Tel Aviv, Israel / Vancouver, Canada, Sept. 18, 2023 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind”), a biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the closing of its United States only public offering made on a reasonable best efforts basis with gross proceeds to the Company of approximately US$2.25 million, before deducting placement agent fees and other expenses payable by the Company. The offering consisted of 7,500,000 common shares and pre-funded warrants and 7,500,000 common warrants. The common warrants are immediately exercisable, will expire five years from the date of issuance and will have an exercise price of US$0.30 (CAD$0.40) per common share. Each common share (or pre-funded warrant in lieu thereof) was sold together with one common warrant at a combined purchase price of US$0.30 (CAD$0.40) per share (or US$0.299 (CAD$0.399) per pre-funded warrant after reducing US$0.001 (CAD$0.001) attributable to the exercise price of the pre-funded warrants) but were issued separately. The common warrants and pre-funded warrants are not listed on any exchange.
The Company expects to use the net proceeds from the offering, for general corporate purposes, which may include operating expenses, research and development, including clinical and pre-clinical testing of its product candidates, working capital, future acquisitions and general capital expenditures.
The offering was not made in Canada and residents of Canada did not purchase any securities in the offering.
Aegis Capital Corp. acted as exclusive placement agent for the offering.
A registration statement on Form F-1 (File No. 333-273293) relating to the offering of the securities was filed with the U.S. Securities and Exchange Commission (SEC) and declared effective by the SEC on September 14, 2023. The offering was made only by means of a prospectus. A final prospectus describing the terms of the proposed transaction is available, on the SEC’s website, www.sec.gov or by contacting Aegis Capital Corp., 1345 Avenue of the Americas, 27th Floor, New York, NY 10105, by telephone at (212) 813-1010 or by email at firstname.lastname@example.org. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which…